Global Heparin Market Insights, Forecast by Type, SWOT Analysis, Detailed Report
Heparin Market Overview
According to latest research by Future Market Insights, heparin market will witness substantial growth during the study period of 2021-2031.Demand for heparin market will elevate in the course of forecast period while experiencing a steady growth.
Adverse effects caused by heparin such as heparin-induced thrombocytopenia is likely to have negative impact, However, Commercialization of cost-effective and safe products, with greater efficacy and lesser side effects is expected to offer new business opportunities.
Heparin Market Dynamics
Heparin is widely used injectable anti-coagulant, which prevents the formation of blood clots. It has its application in pulmonary embolism, deep vein thrombosis, and other cardiovascular surgeries. High incidence of these disorders will augment the market growth.
Also, increasing number of accident cases resulting in surgeries is expected to drive the growth of heparin market across the globe. As per Association for Safe International Travel, in 2020, approximately 4.4 million individuals were severely injured and require immediate medical attention in the U.S. alone. This high number injuries will lead to rise in demand of anti-coagulant agents such as heparin.
Some of the leading manufacturers and suppliers of heparin are
- Aspen Holdings
- Pfizer Inc.
- Leo pharma A/S
- Sanofi
- B. Braun Melsungen AG
- Fresenius SE & Co
- KGaA
- Mylan, N.V.
- Sandoz (Novartis AG)
- Hikma Pharmaceuticals PLC
- Bioiberica S.A.U.
Key Segments of Heparin Market
By Product:
- Low molecular Weight Heparin (LMWH)
- Ultra-Low molecular weight heparin (ULMWH)
- Unfractionated Heparin
By Route of Administration:
- Subcutaneous
- Intravenous
By Route of Application:
- Venous Thromboembolism
- Pulmonary Embolism
- Cardiovascular disorders
- Renal Impairment
- Others
By End Users:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers (ASCs)
For More Information: https://www.futuremarketinsights.com/reports/heparin-market